Results of a Phase II trial of combined chemotherapy for patients with diffuse malignant mesothelioma of the pleura

Cancer

Volumn 85, Issue 8, 1999, Pages 1740-1749

  Kasseyet, Sébastien ^a   Astoul, Philippe ^a,b   Boutin, Christian ^a,b,c  

^a HÔPITAL DE LA CONCEPTION   (France)

^b AIX MARSEILLE UNIVERSITY   (France)

^c APHM and UMR S1076   (France)

Author keywords

5 fluorouracil; Cisplatin; Combined chemotherapy; Etoposide; Growth factors; Malignant pleural mesothelioma; Mitomycin C

Indexed keywords

CISPLATIN; ETOPOSIDE; FLUOROURACIL; FOLINIC ACID; INTERLEUKIN 3; MITOMYCIN C;

ADULT; AGED; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; GASTROINTESTINAL TOXICITY; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; MALIGNANT MESOTHELIOMA; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PLEURA CANCER; PRIORITY JOURNAL; SURVIVAL TIME; TREATMENT OUTCOME;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ASBESTOS; CISPLATIN; COMBINED MODALITY THERAPY; ETOPOSIDE; FEMALE; FILGRASTIM; FLUOROURACIL; HEMATOLOGIC DISEASES; HUMANS; IMMUNOTHERAPY; LEUCOVORIN; MALE; MESOTHELIOMA; MIDDLE AGED; MITOMYCIN; PLEURAL NEOPLASMS; PROSPECTIVE STUDIES; REMISSION INDUCTION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0033561367     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19990415)85:8<1740::AID-CNCR14>3.0.CO;2-9     Document Type: Article

References (45)

1. Alberts A, Falkson G, Goedhals L, Vorobief D, Van Der Herve C. Malignant pleural mesothelioma: a disease unaffected by current therapeutic manoeuvers. J Clin Oncol 1988;6:527-35.
2. Shemin RJ. Surgical treatment of pleural mesothelioma. In: Antman K, Aisner J, editors. Asbestos-related malignancy. Volume 1. Orlando, Florida: Grune and Stratton, 1987:323-37.
3. Hillerdal G. Malignant mesothelioma, 1982: review of 4710 published cases. Br J Dis Chest 1983;77:321-43.
4. Ruffie P, Feld R, Minkin S, Cormier Y, Boutan-Larose A, et al. Diffuse malignant mesothelioma of the pleura in Ontario and Quebec: a retrospective study of 332 patients. J Clin Oncol 1989;7:1157-68.
5. Boutin C, Rey F, Gouvernet J, Viallat JR, Astoul Ph, Ledoray V. Thoracoscopy in pleural malignant mesothelioma: a prospective study of 188 consecutive patients. Part 2. Prognosis and staging. Cancer 1993;72:394-404.
6. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma: a review. J Clin Oncol 1996;14:1007-17.
7. Mattson K, Holsti LR, Tammillehto L, et al. Multimodality treatment programs for malignant pleural mesothelioma using high dose irradiation. Int J Radiat Oncol Biol Phys 1992;24:643-50.
8. Ruffie P. Mesothelioma chemotherapy. Eur Resp Rev 1993; 3:199-203.
9. Chahinian AP, Norton L, Holland JF, Szraja L, Hart RD. Experimental and clinical activity of mitomycin C and cis-Diamminedichloroplatinum in malignant mesothelioma. Cancer Res 1984;44:1688-92.
10. Chahinian AP, Antman K, Goutsou M, Corson JM, Suzuki Y, Modeas C, et al. Randomized phase II trial of cisplatin with mitomycin or doxorubicin for malignant mesothelioma by the Cancer and Leukemia Group B. J Clin Oncol 1993;11: 1559-65.
11. Gerner RE, Moore GE. Chemotherapy of malignant mesothelioma. Oncology 1974;30:152-5.
12. Harvey VJ, Slevin ML, Ponder BAJ, Blackshaw AJ, Wrigley PFM. Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single-agent 5-fluorouracil and adriamycine. Cancer 1984;54:961-4.
13. Schabel FM Jr., Trader MW, Lasker WR Jr., Corbett TH, Griswold DP Jr. Cis-Dichlorodiammineplatinum (II): combination chemotherapy and cross-resistance studies with tumors of mice. Cancer Treat Rep 1979;63:1459-73.
14. International Mesothelioma Interest Group. A proposed new international TNM staging system for malignant pleural mesothelioma. Chest 1995;108:1122-8.
15. Fischer DS, Knobf MT, Durivage HJ. The cancer chemotherapy hand book. 4th edition. St Louis: Mosby; 1993:501-5.
16. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer 1981;47:207-14.
17. Boutin C, Viallat JR, Van Zandwijk N, Douillard JT, Paillard JC, et al. Activity of intrapleural recombinant gamma-interferon in malignant mesothelioma. Cancer 1991;67:2033-7.
18. Boutin C, Rey F, Viallat JR. Prevention of malignant seeding along procedure tracts in pleural mesothelioma: a randomized trial of local radiotherapy. Chest 1995;108:754-8.
19. Zorlu F, Akyol F, Akay H, et al. Preventive irradiation after invasive diagnostic and therapeutic procedures in malignant pleural mesothelioma [letter]. Chest 1996;109: 1665-6.
20. Shin DM, Fossella FV, Umsawasdi T, Murphy WK, Chasen MH, Walsh MH, et al. Prospective study of combination chemotherapy with cyclophosphamide, doxorubicin, and cisplatin for unresectable or metastatic malignant pleural mesothelioma. Cancer 1995;76:2230-6.
21. Law MR, Gregor A, Hodson ME, Bloom HJG. Malignant mesothelioma of the pleura: a study of 52 treated and 64 untreated patients. Thorax 1984;39:255-9.
22. Peto J, Hodgson JT, Matthews FE, Jones JR. Continuing increase in mesothelioma mortality in Britain. Lancet 1995; 345:535-9.
23. Aisner J. Current approach to malignant mesothelioma of the pleura. Chest 1995;107 (6 Suppl):332S-44S.
24. Butchart EG, Ascroft T, Barnsley WC, Holden HP. Pleuropneumonectomy in the management of malignant mesothelioma of the pleura: experience with 29 patients. Thorax 1976;31:15-24.
25. Butchart EG. Surgery of mesothelioma of the pleura. In: Roth JA, Ruckdeschel JC, Weinseinberger TH. Thoracic oncology. Philadelphia: W. B. Saunders Co., 1989:566-83.
26. Rusch VW, Piantadosis S, Holmes EC. The role of extrapleural pneumonectomy in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1991;102:1-9.
27. Gordon W, Antman K, Greenberger J, Weichselbaum R, Chaffey J. Radiation therapy in the management of patients with mesothelioma. Int J Radiat Oncol Biol Phys 1982;8:19-25.
28. Davis SR, Tan L, Ball DL. Radiotherapy in the treatment of malignant mesothelioma of the pleura with special reference to its role in palliation. Australas Radiol 1994;38:212-4.
29. Antman KH, Blum RH, Greenberger JS, Flowerdew G, Skarin AT, Canellos GP. Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med 1980;68:356-62.
30. Sauter ER, Lauger C, Coia IR, Goldberg M, Keller SM. Optimal management of malignant mesothelioma after subtotal pleurectomy: revisiting the role of intrapleural chemotherapy and postoperative radiation. J Surg Oncol 1995;60: 100-5.
31. Colleoni M, Sartori F, Calabro F, Nelli P, Vicario G, Sgarbosse G, et al. Surgery followed by intracavitary plus systemic chemotherapy in malignant pleural mesothelioma. Tumori 1996;82:53-6.
32. Masturk S, Tastepe I, Unlu M, Getin G, Boris Y. Combined chemotherapy in pleurectomized malignant pleural mesothelioma patients. J Chemother 1996;8:159-64.
33. Huncharek M, Kelsey K, Mark EJ, Muscat J, Choi N, Carey R, et al. Treatment and survival in diffuse malignant pleural mesothelioma: a study of 83 cases from the Massachussetts General Hospital. Anticancer Res 1996;16:1265-8.
34. Rusch VW. Pleurectomy/decortication and adjuvant therapy for malignant mesothelioma. Chest 1993;103:382S-4S.
35. Sugarbaker DJ, Heher EC, Lee TH, Couper G, Mentzer S, Corson J, et al. Extrapleural pneumonectomy, chemotherapy and radiotherapy in the treatment of diffuse malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1991;102: 10-5.
36. Sugarbaker DJ, Jaklitsch MT, Liptay MJ. Mesothelioma and radical multimodality therapy: who benefits? Chest 1995; 107:3455-505.
37. Krarup-Hansen A, Hansen HH. Chemotherapy in malignant mesothelioma: a review. Cancer Chemother Pharmacol 1991;28:319-30.
38. Soulié P, Ruffle P, Trandafir L, Monnet I, Tardivon A, Terrier P, et al. Combined systemic chemoimmunotherapy in advanced diffuse malignant mesothelioma: report of a Phase I-II study of weekly cisplatin/interferon alfa-2a. J Clin Oncol 1996;14:878-85.
39. Tansan S, Emri S, Selçuk T, Koç Y, Hesketh P, Heeren T, et al. Treatment of malignant mesothelioma with cisplatin, mitomycin C and alpha interferon. Oncology 1994;51:348-51.
40. Progbeniak H, Kranda K, Steinberg S, et al. Cisplatin, interferon-alpha and tamoxifen (CIT) for malignant pleural mesothelioma [abstract]. Proc Am Soc Clin Oncol 1993;12: A1363.
41. Breau JL, Boaziz C, Morère JF, Sadoun D, Israël L. Chemotherapy with cisplatin, adriamycin, bleomycin and mitomycin C, combined with systemic and intrapleural hyaluronidase in Stage II and III pleura mesothelioma. Eur Respir Rev 1993;3:223-5.
42. Solheim OP, Saeter G, Finnanger AM, Stenwig AE. High-dose methotrexate in the treatment of malignant mesothelioma of the pleura: a phase II study. Br J Cancer 1992;65: 956-60.
43. Belani CP, Herndon J, Vogelzang NJ, et al. Edatrexate for malignant mesothelioma: a phase II study of the Cancer and Leukemia Group B, 9131 [Abstract 1087]. Proc Am Soc Clin Oncol 1994;13:329.
44. Sugarbaker DJ, Norberto JJ. Multimodality management of malignant pleural mesothelioma. Chest 1998;113:61S-5S.
45. Sugarbaker DJ, Flores RM, Jaklitsch MT, Richards WG, Descamp MM, Swanson SJ, et al. Resection margins, N2 status and cell type determine survival in trimodality therapy of malignant pleural mesothelioma (MPM): results in 183 patients [Abstract 33]. AATS, 78th Annual Meeting, Boston, Massachusetts, 1998. Abstract book, 1998: 122.